CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Rituximab to Treat Primary Membranous Nephropathy

Last updated: May 28, 2020
Project Number: HT0032-000 - HS0001-000
Result type: Report
Expected Completion Date: January 5, 2021

Primary membranous nephropathy (MN) is an autoimmune disease that commonly presents as nephrotic syndrome.

The treatment goal of primary MN is to achieve proteinuria remission to prevent renal damage. The current guidelines recommend immunosuppressive therapies such as cyclophosphamide and calcineurin inhibitors (cyclosporine or tacrolimus) to treat this condition. More recently, a randomized controlled trial showed that rituximab was effective in inducing and maintaining proteinuria remission. Its place in therapy compared with currently recommended immunosuppressive therapies is unclear. This Health Technology Assessment will review the available evidence on the use of rituximab for primary MN to determine its place in therapy and its cost-effectiveness relative to cyclophosphamide and calcineurin inhibitors.

Projects listed as “in progress” are at various stages and points of completion. These products have different processes and timelines; therefore, the timing of posting of the final reports varies and expected completion dates may change. Find out more about Projects in Progress.

The “Projects in Progress” page on the CADTH website is updated on a seven- to eight-day cycle. Please be advised that there may be overlap between when a new report is posted online and when the section is updated. View our current Projects in Progress.